Biotalys’ Post

Biotalys today announced its key #business achievements and consolidated #financial results for the first half of 2024. Kevin Helash, Chief Executive Officer of Biotalys, noted: “The first half of 2024 heralded key #milestones for Biotalys in our mission to transform crop protection, such as the partnership with Novonesis for EVOCA NG and the initiation of field trials for BioFun-6, our second biofungicide candidate. Further to the development of EVOCA, I am very pleased to announce we just received approval by the Dutch regulatory authority to do large scale #demonstration #trials with the product in the Netherlands. The authority has also allowed the sale of the #harvested produce for human consumption.” Helash added: “As a result of the measures implemented at the end of last year to control costs, we have been able to considerably reduce our operating cash burn in the first half of this year. We will continue to concentrate our #resources on applying the targeted approach to our research platform, as well as on progressing our various pipeline programs. We will consider additional financing such as through equity, newly awarded grants and partnerships to execute our strategy to transforming crop protection.” Read the full press release here: https://lnkd.in/g8zrwVJ

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics